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AbstrACt 
Introduction The emergence of mobile health (mHealth) 
solutions, particularly mHealth applications (apps), has 
shown promise in self-management of chronic diseases 
including type 2 diabetes mellitus (T2DM). While majority 
of the previous systematic reviews have focused on the 
effectiveness of mHealth apps in improving treatment 
outcomes in patients with T2DM, there is a need to also 
understand how mHealth apps influence self-management 
of T2DM. This is crucial to ensure improvement in the 
design and use of mHealth apps for T2DM. This protocol 
describes how a systematic review will be conducted to 
determine in which way(s) mHealth apps might impact on 
self-management of T2DM.
Methods The following electronic databases will be 
searched from inception to April 2019: PubMed, MEDLINE, 
EMBASE, Global Health, PsycINFO, CINAHL, The Cochrane 
Central Register of Controlled Trials, Scopus, Web of 
Science, ProQuest Dissertations & Theses Global, Health 
Management Information Consortium database, Google 
Scholar and  ClinicalTrials. gov. The Cochrane risk of bias 
tool will be used to assess methodological quality. The 
primary outcome measures to be assessed will be ‘change 
in blood glucose’. The secondary outcomes measures will 
be ‘changes in cardiovascular risk markers’ (including 
blood pressure, body mass index and blood lipids), and 
self-management practices. Others will include: health-
related quality of life, economic data, social support, 
harms (eg, death or complications leading to hospital 
admissions or emergency unit attendances), death from 
any cause, anxiety or depression and adverse events (eg, 
hypoglycaemic episodes).
Ethics and dissemination This study will not involve 
the collection of primary data and will not require ethical 
approval. The review will be published in a peer-reviewed 
journal and a one-page summary of the findings will 
be shared with relevant organisations. Presentation of 
findings will be made at appropriate conferences.
trial registration number CRD42017071106.
IntroduCtIon
Diabetes is a long-term condition and a 
leading cause of morbidity and mortality 
world-wide.1 The past three decades have seen 
the most dramatic increase in the number of 
adults living with diabetes by almost a four-
fold, from 108 million in 1980 to 422 million 
in 2014.2 Type 2 diabetes mellitus (T2DM), 
the most common type of diabetes in adults, 
accounts for over 90% of all diabetes cases.1 3 
When T2DM is poorly managed, it can easily 
result in systemic complications such as coro-
nary heart disease, stroke, kidney failure, reti-
nopathy and foot ulcers.4 These complications 
can further progress to severe disabilities. 
For example, diabetic foot ulcers can lead to 
non-traumatic limb amputation and diabetic 
retinopathy can result in blindness.4 Compli-
cations and disabilities resulting from poorly 
managed T2DM often cause increased socio-
economic burden with associated reduced 
quality of life and reduced life expectancy.5 6 
A landmark study estimated the cost of type 2 
strengths and limitations of this study
 ► This study will extend its focus beyond assessing 
effectiveness in improving treatment outcomes to 
understanding how mobile health (mHealth) appli-
cations (apps) might influence self-management of 
type 2 diabetes mellitus (T2DM).
 ► The methodological quality of all included trials in 
this study will be thoroughly assessed in order to 
ascertain the validity of their findings.
 ► Robust subgroup analyses will provide an under-
standing of how certain factors or patient char-
acteristics (such as ethnicity and presence of 
comorbidities) might affect self-management of 
T2DM when using mHealth apps.
 ► A wide range of databases will be searched to en-
sure that potentially relevant studies are not missed.
 ► Since only studies published in English language 
will be considered for this review, this might intro-
duce some bias. However, we are aware that studies 
with significant findings are likely to be published in 
English language so as to increase their chances of 
being cited by others.
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diabetes mellitus in the UK in 2010/2011 at £8.8 billion in 
direct costs and £13 billion in indirect costs.7 The severity 
of the burden of T2DM has further heightened the need 
to improve its treatment and management.
The treatment of T2DM primarily aims to control 
blood glucose thereby preventing or reducing associated 
complications and disabilities.6 Over the years, there has 
been a growing body of evidence to support the role that 
self-management plays in the treatment of T2DM.8–12 
Self-management is a term used to describe patient’s own 
responsibilities (including practices and skills) employed 
in maintaining good health.13 14 The documented prac-
tices and skills which form critical components of the 
management of T2DM are mainly healthy eating, physical 
activity, blood sugar monitoring, medication adherence, 
good problem-solving skills, healthy coping skills and 
risk-reduction behaviours.10 11 13 14
Mobile health (mHealth) solutions, which include 
mobile applications (apps), have been rapidly gaining 
popularity in the management of chronic diseases and 
have further created opportunities and potential to 
enhance the ability of T2DM patients for self-manage-
ment.15–17 A mobile app is a software application designed 
to run on smartphones, tablet computers or similar 
mobile devices.18 When mobile apps are used for health 
purposes, they are often referred to as mHealth apps. 
They have the ability to facilitate one or more aspects 
of self-management by capturing user’s health data and 
providing tailored information, instructions, graphic 
displays, guidance and reminders to users.18–20 In addi-
tion, mHealth apps are designed with aesthetical features 
to appeal to users and can provide a portable platform 
for remote monitoring of patient’s data as well as links to 
their healthcare providers and social networks.18–21 More 
specifically, the definition of mHealth app for self-man-
agement of T2DM in the context of this study is adapted 
from Pal et al19 as any mobile application which utilises 
input from a patient by means of communication or 
processing technology to provide tailored responses that 
facilitate one or more aspect of self-management of T2DM 
(healthy eating, physical activity, blood sugar monitoring, 
medication adherence, good problem-solving skills, 
healthy coping skills and risk-reduction behaviours).19
Although mHealth apps seem promising for influ-
encing self-management of T2DM,22 concerns have been 
raised about their quality and safety following evalua-
tion studies which showed that some of these apps are 
either poorly designed, do not function as intended 
or do not adhere to evidence-based guidelines.20 21 23 24 
While previous systematic reviews showed modest bene-
fits of mHealth apps in self-management of T2DM, they 
focused on assessing effectiveness in improving treat-
ment outcomes rather than understanding how these 
mHealth apps most effectively influence self-manage-
ment of T2DM.16 19 25–28 The use of mHealth apps, espe-
cially in the context of self-management, is a complex 
intervention (influenced by several interacting compo-
nents including healthy eating, physical activity, blood 
sugar monitoring, medication adherence, good prob-
lem-solving skills, healthy coping skills and risk-reduction 
behaviours).29 Therefore, extending the focus beyond 
assessing effectiveness to understanding how (including 
when and where) mHealth apps influence self-manage-
ment of T2DM is extremely important. This will provide 
evidence and direction for better design, implementation 
and ultimately, the optimum use of mHealth apps for 
self-management of T2DM.
In this article, we present a protocol which describes 
how a systematic review will be conducted to determine in 
what way(s) mHealth apps might impact on self-manage-
ment of T2DM and thus provide an additional perspec-
tive on how (including when and where) mHealth apps 
may influence self-management of T2DM. The protocol 
is presented in accordance with the guideline of the 
Preferred Reporting Items for Systematic Review and 
Meta-Analysis Protocol (PRISMA-P).30 A completed PRIS-
MA-P checklist is provided as online supplementary file 1.
AIM And rEsEArCh quEstIon
The aim is to determine how mHealth apps might impact 
on self-management of T2DM. The review will attempt to 
answer a crucial research question, which to the best of 
our knowledge has not been fully answered by previous 
systematic reviews; that is, how does the use of mHealth 
apps impact on self-management of T2DM in patients 
compared with other interventions?
MEthods
study design
A team comprising of experts from the relevant disciplines 
(diabetes management, information and communication 
technologies and systematic review methodology) will 
design, conduct and report the systematic review. The 
formation of the review question and search strategy was 
guided by the Participants, Intervention, Comparison, 
Outcomes framework.31 32 The process of the systematic 
review will follow the methods described in the Cochrane 
Handbook for Systematic Reviews of Interventions.33 The 
reporting of the review will be guided by the Preferred 
Reporting Items for Systematic Review and Meta-Analysis 
(PRISMA) statement.34
study registration
This systematic review is registered with PROSPERO ( 
www. crd. york. ac. uk/ PROSPERO). Registration number: 
CRD42017071106.
Criteria for considering studies for this review
Type of studies
Only randomised controlled trials (RCTs) will be 
included in this review with no restriction in the duration 
of follow-up. The Consolidated Standards of Reporting 
Trials checklist will be used to judge the reliability or 
relevance of the findings of RCTs that will be included 
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in this review.35 The risk of bias will be assessed using the 
Cochrane Collaboration’s tool.33
Types of participants
Patients diagnosed with T2DM will be considered for 
this review. Studies that included both type 1 and type 2 
diabetes patients will also be considered; however, only 
data on patients with type 2 diabetes will be extracted. 
Studies targeted at only patients with type 1 diabetes will 
not be considered. There will be no age restriction, but 
participants will be categorised by age group: ≤39 years, 
40 to 65 years and >65 years. Older patients are likely to 
have more diabetes comorbid conditions (such as raised 
blood pressure) than younger patients,6 while younger 
patients are likely to be more digitally literate and thus 
more inclined to use mHealth.36
Diagnostic criteria for T2DM
T2DM is characterised by hyperglycaemia resulting from 
progressive insulin resistance and deficiency.37 For consis-
tency, the current WHO/International Diabetes Feder-
ation diagnostic criteria for diabetes will be maintained; 
that is, fasting blood glucose ≥7.0 mmol/L (126 mg/
dL) or 2 hour blood glucose ≥11.1 mmol/L (200 mg/
dL).38 Where glycated haemoglobin (HbA1c) is used as 
a diagnostic criterion, the WHO recommended value 
of ≥6.5% will be used.39 Where diagnostic criteria are not 
stated, authors will be contacted.
Types of intervention
Only studies on self-management of T2DM that utilised 
mHealth apps alone, mHealth app along with usual care 
or mHealth apps along with a range of other technolo-
gies such as wearable devices (for example, pedometer) 
or mHealth apps in conjunction with other mHealth 
solutions such as texting or messaging will be included 
in this review. Studies that used mHealth solutions (such 
as emailing and texting) exclusively for communica-
tion between patients and health professionals or social 
networks; or targeted exclusively at health professionals 
will not be considered for this review as they provide 
limited functionality for self-management.
Types of comparison/control
Comparisons will be made against any type of control. 
This may include, but not limited to, standard or usual 
care, dummy apps or control apps, face-to-face self-man-
agement education, use of paper educational materials, 
other mHealth solutions (for example, messaging or 
texting), computer-based and/or web-based self-manage-
ment interventions.40
Types of outcome measures
The outcome measures of this review will be reported 
as primary and secondary outcomes based on reported 
outcomes of included studies.
The primary outcomes will be ‘change in blood glucose’ 
often reported as glycated haemoglobin (HbA1c). HbA1c 
is the gold standard for assessing glycaemic control in 
diabetic patients and each measurement represents 
average blood glucose over the previous 2 to 3 months. 
HbA1c measurement does not require any special prepa-
ration such as fasting and it can be done at any time of 
the day.38 If fasting blood glucose is reported rather than 
HbA1c in some included studies, it will then be consid-
ered as the primary outcome measure; however, it will be 
converted to an estimated HbA1c value.
The secondary outcomes will include ‘changes in cardio-
vascular risk markers (blood pressure, body mass index, 
low-density lipoprotein cholesterol, high-density lipopro-
tein cholesterol and triglyceride), patient’s knowledge on 
T2DM and self-management and adherence to self-man-
agement practices. Others will include: health-related 
quality of life, economic data (such as cost-effectiveness), 
social support, harms (such as death or complications 
leading to hospital admissions or emergency unit atten-
dances), death from any cause, anxiety or depression and 
adverse events (for example, hypoglycaemic episodes).40
Timing of outcome measurement
Where possible, the impact of the intervention at different 
timings will be measured. The timing will be grouped 
into three categories of follow-up as follows: short-term, 
medium-term and long-term. Short-term follow-up will 
be defined as that measured within 33 months of the 
intervention period in order to determine the immediate 
changes resulting from the intervention. Medium-term 
follow-up will be defined as that measured between 33 and 
66 months of the intervention period to determine if the 
changes continue. Long-term follow-up will be defined as 
66 months and over after the intervention to determine 
whether there are changes over time.40 For the overall 
meta-analysis, the longest follow-up data available will be 
used.
Search strategy for the identification of studies
Using the key terms (type 2 diabetes mellitus, self-man-
agement, mobile health, mHealth and mobile applica-
tion), a comprehensive search strategy will be designed 
by two reviewers (BAB and SOC) with the assistance of 
a librarian and in consultation with other research team 
members. The search strategy will be used to search for 
all eligible studies including articles, dissertations, theses, 
conference proceedings and grey literature (including 
committee reports and government reports). Online trial 
registers for ongoing and recently completed studies will 
also be searched. While no restriction will be placed on 
dates, only studies reported in English language will be 
considered.
The following electronic databases will be searched 
from their inception to April 2019:
PubMed, MEDLINE, EMBASE, Global Health, 
PsycINFO, CINAHL, The Cochrane Central Register 
of Controlled Trials, Scopus, Web of Science, ProQuest 
Dissertations & Theses Global, Health Management 
Information Consortium database, Google Scholar and 
ClinicalTrials. gov.
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Additional studies will be identified by searching the 
reference lists of included studies as well as reference list 
of relevant systematic reviews and meta-analyses.
A re-run of the entire searches will be done just before 
the final analyses and any additional studies found will be 
included.
A sample search strategy for MEDLINE is provided in 
online supplementary file 2.
Selection of studies
All identified articles will be imported into Mendeley 
reference management software, and duplicates will be 
removed. The articles will then be imported into Covi-
dence (a web-based tool to support the reviewers to 
manage the data). Two reviewers working independently 
will screen each article for possible inclusion in the 
review. The screening will be done in two stages (title 
and abstract, and full text) based on predefined eligi-
bility criteria as highlighted in table 1. To ensure consis-
tency in the screening process, the two reviewers (BAB 
and SOC) will pilot the entire process on 10 studies as 
guided by the Cochrane Collaboration Study Selection 
and Data Extraction form.33 A consensus will be reached 
after discussing and refining the process. The reasons 
for excluding any study will be published with the main 
study. Any disagreement will be resolved by discussion 
and where there is an unresolved disagreement, a third 
party (JOD) will be invited to resolve the issue which 
will be justified in a steering group meeting. The entire 
selection processes will be described using the Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
yses (PRISMA) flow diagram.34 The PRISMA checklist will 
be completed and attached as an additional file.
Data extraction and management
Two reviewers (BAB and SOC) working independently 
will extract the characteristics of selected studies using 
standard data extraction templates as guided by the 
Cochrane Collaboration Study Selection and Data 
Extraction form.33 Any disagreement will be resolved 
by discussion. Where there are inconsistencies or unre-
solved disagreements, a third party (JOD) will be invited 
to resolve the issue which will be justified in a steering 
group meeting. To ensure consistency in the extraction 
process, it will be initially piloted on at least 1010 per cent 
of the articles and a consensus reached after discussing 
and refining the process. Any missing information that 
is relevant to this review will be sought from the original 
authors of the article by email.
The following characteristics will be included if 
reported in individual studies41 :
 ► Publication details: authors, year and country of study.
 ► Methods: study design, baseline measure, time points 
(when data were collected: at baseline and endpoint) 
and study setting (location, year and environment).
 ► Participant characteristics: number of participants, 
mean age or age range, gender ratio, ethnicity, soci-
oeconomic group, educational status, duration of 
T2DM and participant inclusion criteria and exclu-
sion criteria.
 ► Intervention: description of the content and func-
tions design of the mHealth apps used, the aspects of 
self-management, number of participants allocated to 
the intervention group, other technologies or inter-
ventions used and duration.
 ► Control/comparison(s) group: description of the 
comparison(s) and number of participants allocated 
to the control group.
Table 1 Predefined criteria for inclusion in the systematic 
review
Acronym Term Description
P Population Patients with T2DM as defined by WHO 
& IDF diagnostic criteria.38 39
I Intervention Studies on self-management of 
T2DM that utilised mHealth apps 
alone, mHealth apps along with usual 
care or along with a range of other 
technologies such as a wearable device 
(eg, pedometer) or mHealth apps in 
conjunction with other mHealth solutions 
such as texting/messaging.
C Comparison The control groups be used for 
comparison. These may include standard 
or usual care, dummy apps or control 
apps, face-to-face self-management 
education, use of paper educational 
materials, other mHealth solutions 
(for example, messaging or texting), 
computer-based and/or web-based self-
management interventions.
O Outcomes Primary outcomes will be change 
in blood glucose (HbA1c). The 
secondary outcomes will include 
changes in cardiovascular risk markers 
(BP, BMI, LDL-C, HDL-C and TG), 
patient’s knowledge on T2DM and 
self-management, and adherence to 
self-management practices. Others 
will include health-related quality of 
life, economic data (such as cost-
effectiveness), social support, harms 
(such as death or complications leading 
to hospital admissions or emergency 
unit attendances), death from any cause, 
anxiety or depression and adverse events 
(eg, hypoglycaemic episodes).
S Study type Randomised controlled trials.
T Timing of 
outcome 
measure
There will be no restriction to the 
timing of outcome measures, however, 
the timing will be grouped into three 
categories: short-term (≤3 months of 
the intervention period), medium-term 
(3 to 6 months of the intervention period 
and long-term (≥6 months after the 
intervention).
apps, applications; BP, blood pressure; BMI, body mass index; 
HbA1c, glycated haemoglobin; HDL-C, high-density lipoprotein 
cholesterol; IDF, International Diabetes Federation; LDL-C, low-
density lipoprotein cholesterol; mHealth, mobile health; TG, 
triglyceride; T2DM, type 2 diabetes mellitus. 
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 ► Outcomes: description of primary, secondary and 
other outcomes, list of measurement tools and devices, 
unit of measurement for outcomes and intervention 
effects on the outcomes (effect size, 95% CI, standard 
mean deviation).
 ► Additional information: any information that may 
express conflict of interest or bias will be noted.
Assessment of risk of bias in included studies
Each study will be assessed independently by two reviewers 
(BAB and NM). Any disagreements will be resolved by 
discussion, or if required, a third party (JOD).
The following bias criteria will be used to assess the risk 
of bias as recommended in the Cochrane Handbook for 
Systematic Reviews of Interventions33:
 ► Random sequence generation (selection bias).
 ► Allocation concealment (selection bias).
 ► Blinding (performance bias and detection bias), sepa-
rated for blinding of participants and personnel and 
blinding of outcome assessment.
 ► Incomplete outcome data (attrition bias).
 ► Selective reporting (reporting bias).
 ► Other bias.
The risk of bias criteria for RCTs will be judged as ‘low 
risk’, ‘high risk’ or ‘unclear risk’ and the use of individual 
bias items as described in the Cochrane Handbook for 
Systematic Reviews of Interventions.33 A ‘risk of bias 
graph’ figure and ‘risk of bias summary’ figure will be 
attached. The impact of individual bias domains on study 
results at endpoint and study levels will be assessed.
dAtA synthEsIs
Both qualitative and quantitative analyses are planned for 
this review.
qualitative synthesis
For the qualitative analysis of this review, a narrative 
synthesis approach will be adopted based on the Guid-
ance on the Conduct of Narrative Synthesis in Systematic 
Reviews.42 Popay et al defined narrative synthesis as ‘an 
approach to the systematic review and synthesis of find-
ings from multiple studies that relies primarily on the use 
of words and text to summarise and explain the findings 
of the synthesis’.42
Narrative synthesis approach is adopted for this review 
so as to develop a preliminary synthesis, explore relation-
ships within and between studies and assess the robustness 
of the synthesis.42 In preliminary synthesis, the results of 
included studies are laid out in a systematic manner to 
give an overview of the relationships among them allowing 
for comparison of direction and size of effects, which 
will be further explored in the next step. The next step 
involves examining the relationships within and between 
studies categorising and explaining factors responsible 
for the differences in direction and effects as well as the 
interplay of factors that may influence effectiveness and 
successful implementation. Finally, the entire process of 
narrative synthesis allows for the methodological quality 
of included studies to be scrutinised thereby increasing 
the robustness of the review.
quantitative synthesis
Statistical analyses will be performed based on recom-
mendation in the Cochrane Handbook for Systematic 
Reviews of Interventions.43 Summaries of intervention 
effects for each study will be calculated using risk ratios 
(for dichotomous outcomes) or standardised mean differ-
ences (for continuous outcomes). For meta-analysis, it is 
anticipated that there will be limited scope for the use of 
fixed-effect model because of the possibility of a range 
of different outcome measures and also, the effect sizes 
are not likely to be identical across studies.44 For instance, 
the magnitude of the impact of mHealth apps alone or 
along with other technologies (such as wearable devices) 
or in conjunction with other interventions on self-man-
agement might vary. Therefore, random-effects model 
will be used as the weights assigned under random effects 
are more balanced.44
Measures of treatment effect
Dichotomous data
The effect size for dichotomous data will be expressed as 
risk ratios and 95% CI. The risk difference will be calcu-
lated as well as the number needed to treat for an addi-
tional beneficial outcome or the number needed to treat 
for an additional harmful outcome, when possible.
Continuous data
For continuous outcomes, weighted mean differences 
and 95% CI will be calculated. If results for some contin-
uous outcomes are found on different scales and cannot 
be converted to a standard scale standardised mean 
differences will be used.
Time-to-event data
The results will be expressed as HR with corresponding 
95% CI.
Unit of analysis issues
The review will take into account the level at which rando-
misation occurred, such as cross-over trials, cluster-ran-
domised trials and multiple observations for the same 
outcome.
dealing with missing data
Relevant missing data will be obtained from original 
authors if feasible and an evaluation of important 
numerical data such as numbers of screened articles, 
randomised patients, intention-to-treat, as-treated and 
per-protocol population will be done. Attrition rates, for 
example dropouts, losses to follow-up and withdrawals 
will be investigated and issues of missing data and impu-
tation methods (for example, last observation carried 
forward) will be critically appraised.
 o
n
 26 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025714 on 25 June 2019. Downloaded from 
6 Bene BA, et al. BMJ Open 2019;9:e025714. doi:10.1136/bmjopen-2018-025714
Open access 
Assessment of heterogeneity
In the event of substantial clinical or methodological or 
statistical heterogeneity, report of study results will not be 
presented as pooled effect estimates. Heterogeneity will 
be identified by visual inspection of the forest plots and by 
using a standard X2 test with a significance level of α=0.1, 
in view of the low power of this test. Specifically, hetero-
geneity will be examined by employing the I2 statistic 
which quantifies inconsistency across studies to assess the 
impact of heterogeneity on the meta-analysis,45 46 where 
an I2 statistic of 75% and more indicates a considerable 
level of inconsistency.43 When heterogeneity is found, an 
attempt will be made to determine potential reasons for 
it by examining individual study and subgroup character-
istics. This will be reported as qualitative analysis using 
narrative synthesis.
Assessment of reporting biases
To assess small study bias, funnel plots will be used if more 
than 10 studies are included for a given outcome.
subgroup analyses
Subgroup analyses will be performed for the purpose of 
assessing whether or not there exist any differences in the 
primary outcome influenced by certain factors or patient 
characteristics; however, there are scepticisms about the 
credibility of subgroup effects.47–49 Therefore, we will 
ensure that subgroup analyses are conducted majorly if 
the primary outcome of any included trial shows statisti-
cally significant differences between intervention groups. 
Where a trial reports differences in treatment outcome 
between intervention groups but fails to demonstrate 
any statistical significance, subgroup analyses will only be 
carried out to generate hypotheses.49 Thus, the following 
subgroup analyses are planned:
 ► Ethnicity/country of origin: An American study 
compared Hispanics with non-Hispanic Whites, who 
participated equally in a diabetes education class, and 
found that Hispanics were less likely to check their 
blood glucose daily or examine their feet for any 
abnormality. They were, however, more likely to take 
oral hypoglycaemic agents than non-Hispanic White.50 
Another study showed that Chinese Americans were 
more engaged than African Americans in improving 
most self-management behaviours.51 We will perform 
a subgroup analysis to see the effect of ethnicity on 
self-management of T2DM when using mHealth apps.
 ► Comorbidities: A study found that diabetes patients 
who had higher number of comorbidities placed 
lower priority on their disease and hence scored low 
in their self-management ability.52 This is likely to 
affect blood glucose control. Our study will attempt to 
find out if this hypothesis holds true for self-manage-
ment of T2DM when using mHealth apps.
 ► Behaviour change model used: Technology-based 
interventions for diabetes have the potential to 
improve self-management; however, it has been 
argued that in order to achieve the desired patient 
benefit or treatment outcome, their design must be 
guided by behaviour change or self-care theories.53 
We will carry out a subgroup analysis to find out if this 
hypothesis also holds for mHealth apps for self-man-
agement of T2DM.
sensitivity analyses
Sensitivity analyses will be performed in order to explore 
the influence of the following factors on effect size:
 ► Restricting the analysis to published studies (RCTs).
 ► Restricting the analysis taking account risk of bias, as 
specified above.
 ► Restricting the analysis to long (≥12 months) or 
studies with relatively larger sample sizes to establish 
how much they dominate the results.
 ► Restricting the analysis to studies using the following 
filters: diagnostic criteria, source of funding (industry 
vs other) and country.
The robustness of the results will be tested by repeating 
the analysis using different measures of effect size (rela-
tive risk, odd ratio etc) and different statistical models 
(fixed-effect model and random-effects model).
PAtIEnt And PublIC InvolvEMEnt
Although patients and the public were not directly 
involved in the design of this study, the development of 
the research question was primarily informed by patients’ 
interests in the research outcomes.
EthICs And dIssEMInAtIon
This study does not involve collection of primary data 
from patients, hence it will not require ethical approval.
A manuscript will be submitted to a peer-reviewed 
journal for publication. Likewise, a summary of the find-
ings will be shared with relevant and responsible organisa-
tions. In addition, important findings will be summarised 
and presented at national and international conferences 
such as the Diabetes UK Annual Scientific Meeting, and 
Society for Academic Primary Care National Meeting.
dIsCussIon
The use of mHealth apps for self-management is a complex 
intervention because of the several interacting compo-
nents involved (including healthy eating, physical activity, 
blood sugar monitoring, medication adherence, good 
problem-solving skills, healthy coping skills and risk-reduc-
tion behaviours). Hence, improving the design and use of 
mHealth apps for self-management of T2DM will require an 
understanding of how mHealth apps are likely to be most 
effective in influencing self-management of T2DM. The 
majority of previous studies primarily assessed the effective-
ness of mHealth apps in improving health outcomes,16 25 26 28 
but this study will extend its focus to understanding how 
(including when and where) mHealth apps might influ-
ence self-management of T2DM. We will perform subgroup 
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analyses to assess any differences in the primary treatment 
outcome based on certain factors or patient characteristics 
such as ethnicity and the presence or absence of comorbid-
ities. However, where a trial report suggests differences in 
treatment outcome between intervention groups but fails to 
demonstrate any statistical significance, subgroup analyses 
will only be carried out to generate hypotheses.
To our knowledge, this is the first published protocol that 
describes how a systematic review will be conducted to eval-
uate the impact mHealth apps might have on self-manage-
ment of T2DM. In addition, this review will ensure robust 
assessment of methodological quality of included trials in 
order to ascertain the validity of their findings and to ensure 
that the risks of bias were minimised.33 54
In most of the previous systematic reviews, limited data-
bases were searched. For instance, Cui et al26 and Liang et al16 
searched three databases while Frazetta et al28 searched two 
databases.16 26 28 In this review however, a wide range of data-
bases will be searched to ensure that potentially relevant 
studies are not missed. Although only studies published in 
English language will be considered for this review, we are 
cognisant of the fact that studies with significant findings are 
likely to be published in English language so as to increase 
their chances of being cited by others.55
Finally, it is expected that the evidence which will be 
generated from this study will add a new perspective that 
will be useful in informing improvement and/or optimi-
sation of design and use of mHealth apps for self-man-
agement of T2DM; thus, potentially improving health 
outcomes in patients with T2DM.
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